CLINICAL_TRIALS
trial_result
· 2011-11-29
Clinical Trial Update: A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept
Summary
A completed clinical study evaluating the receptor occupancy of CD86 and CD80 by abatacept in rheumatoid arthritis patients initiating therapy.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Astellas Pharma Inc | Conditions: Rheumatoid Arthritis | Status: COMPLETED